Tiziana Life Sciences (TLSA) announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosi, na-SPMS. The University of Massachusetts, UMass, has now joined Brigham and Women’s Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University Autoimmunity Center of Excellence in actively dosing participants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Expands Phase 2 Trial for Multiple Sclerosis Treatment
- Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab
- Tiziana Life Sciences files $250M mixed securities shelf
- Tiziana Life Sciences announces dosing of new patients at Yale MS Center
- Tiziana Life Sciences CEO to Present at ROTH Conference